Implied DSI Analyst Target Price: $130
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy MD?
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares ESG MSCI KLD 400 ETF (DSI) has an implied analyst target price of $129.70, indicating a potential upside of 20.83% from its current trading price of $107.34.
Notable Holdings with Upside Potential: Key underlying holdings such as Teradata Corp, Pediatrix Medical Group Inc, and Teladoc Health Inc show significant upside potential based on analysts' target prices, raising questions about the validity of these targets amidst market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MD
Wall Street analysts forecast MD stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 21.390
Low
23.00
Averages
23.50
High
24.00
Current: 21.390
Low
23.00
Averages
23.50
High
24.00
About MD
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pediatrix Expands Maternal-Fetal Care in Tennessee
- Service Expansion: Pediatrix Medical Group enhances its service network in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, ensuring high-quality maternal-fetal care for expectant mothers in the Greater Nashville area and strengthening its market position in this sector.
- Expert Team: The practice comprises four board-certified physicians and six advanced practice providers, offering comprehensive maternal-fetal medicine services, thereby enhancing Pediatrix's ability to meet the growing maternal care needs in Middle Tennessee.
- Strategic Partnership: This collaboration not only elevates Pediatrix's specialty services but also integrates the national reputation of Tennessee Maternal-Fetal Medicine, which is expected to positively impact the company's future revenue streams.
- Financial Impact: The transaction is a cash deal and is anticipated to be immediately accretive to Pediatrix's earnings, further solidifying its leadership position in the maternal-fetal medicine market.
See More
Pediatrix Appoints Two Quality Care Experts
- Executive Appointments: Pediatrix Medical Group has announced the appointment of Dr. James Barry as Chief Clinical Quality & Transformation Officer and Dr. Jochen Profit as Chief Quality Advisor, both renowned for their expertise in care quality, which is expected to enhance the company's service quality for women, babies, and children.
- Quality Improvement Strategy: Dr. Barry will be responsible for shaping the medical direction of the organization, ensuring the highest standards of patient care, and overseeing the work of the Pediatrix Center for Research, Education, Quality and Safety, aimed at improving patient experience and reducing healthcare costs through clinical research and continuous quality improvement.
- Innovation and Leadership: Dr. Barry's contributions in neonatal critical care and medical artificial intelligence will provide strategic advantages for Pediatrix, as his experience will help the company maintain competitiveness in a rapidly evolving healthcare environment.
- Research and Optimization: Dr. Profit's research on optimizing care delivery for pregnant individuals and newborns will provide expert guidance for Pediatrix, advancing the company's efforts in health equity and family-centered care, thereby enhancing patient safety and care quality.
See More
Pediatrix Hosts 47th Annual Neonatology Conference
- Neonatology Conference: Pediatrix Medical Group is hosting the 47th Annual NEO Conference from February 25-27 in Las Vegas, bringing together leading experts to discuss the latest research and innovations in neonatal medicine aimed at improving newborn care outcomes.
- Preterm Birth Rates: The March of Dimes' 2025 Report Card indicates that the national preterm birth rate remains at 10.4%, meaning one in ten newborns is born prematurely, underscoring the ongoing need for innovation in neonatal-perinatal medicine.
- Continuing Education Opportunities: Attendees can earn up to 20 AMA PRA Category 1 Credits and 20 nursing contact hours, reflecting Pediatrix's commitment to enhancing the skills and knowledge of healthcare professionals in the field.
- Hall of Fame Induction: During the conference, Dr. Waldemar Carlo will be inducted into the Legends of Neonatology Hall of Fame, recognizing his pioneering research in neonatal resuscitation and global health initiatives, further advancing neonatal care practices.
See More
Pediatrix Medical Group Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Pediatrix Medical Group reported an adjusted EBITDA of $66 million for Q4 2025, consistent with upwardly adjusted guidance, reflecting robust business volume, acuity, and payer mix, which underscores effective financial control within the organization.
- New Incentive Programs: The introduction of a stock price performance-linked bonus program and the Pediatrix Partners leadership group, comprising 46 physicians receiving stock tracking grants, aims to enhance organizational cohesion and clinical leadership, aligning with the company's strategic objectives.
- 2026 Outlook: Management projects adjusted EBITDA for 2026 to be between $280 million and $300 million, indicating a 5% growth at the midpoint compared to 2025, while anticipating flat revenue, which reflects a cautious approach to market conditions.
- Cash Flow and Share Repurchase: The company generated $115 million in operating cash flow in Q4, down from the previous year, and repurchased 2.9 million shares during the quarter, reducing outstanding shares to approximately 83 million, demonstrating a disciplined approach to capital allocation.
See More
Pediatrix Medical Group Shares Plunge 12% Following Earnings Report
- Disappointing Earnings: Pediatrix Medical Group reported fourth-quarter revenue of nearly $493.8 million, down almost 2% year-over-year, indicating pressure in the competitive healthcare services market, despite analysts' expectations of $486.2 million.
- Declining Net Income: The company's non-GAAP net income fell to $42.5 million ($0.50 per share), down from $43.5 million a year ago, reflecting challenges in cost control amid rising operational expenses.
- Increased Bonus Payouts: The tightening labor market for healthcare professionals led to significantly higher bonus payouts, negatively impacting the company's bottom line and raising investor concerns about future profitability.
- Cautious Future Outlook: Pediatrix anticipates adjusted EBITDA of $280 million to $300 million for full-year 2026, which, while an increase from last year's $275.6 million, still reflects analysts' tepid growth expectations, contributing to diminished market confidence.
See More
Pediatrix Medical Group Reports Q4 2025 Earnings Results
- Financial Performance Overview: Pediatrix Medical Group reported net revenue of $494 million and net income of $34 million for Q4 2025, with an adjusted EPS of $0.50, indicating stable operational capacity despite a slight decline in revenue compared to the previous year, aligning with the company's upwardly revised expectations.
- Same-Unit Revenue Growth: The same-unit revenue increased by 4.0% in Q4 2025, primarily driven by improved collection activities and higher patient acuity, although patient service volumes decreased by 2.7%, demonstrating resilience in market demand, particularly in hospital-based services.
- Cost Control and Adjustments: Operating expenses for Q4 were $444 million, down from $463 million in the prior year, mainly due to the impact of practice dispositions, despite rising clinical compensation costs, reflecting the company's efforts in cost management.
- Future Outlook: Pediatrix anticipates its 2026 adjusted EBITDA to range between $280 million and $300 million, showcasing confidence in future growth, particularly as the company continues to invest in innovation and service quality amid challenges in the healthcare industry.
See More
Pediatrix Expands Maternal-Fetal Care in Tennessee
- Service Expansion: Pediatrix Medical Group enhances its service network in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, ensuring high-quality maternal-fetal care for expectant mothers in the Greater Nashville area and strengthening its market position in this sector.
- Expert Team: The practice comprises four board-certified physicians and six advanced practice providers, offering comprehensive maternal-fetal medicine services, thereby enhancing Pediatrix's ability to meet the growing maternal care needs in Middle Tennessee.
- Strategic Partnership: This collaboration not only elevates Pediatrix's specialty services but also integrates the national reputation of Tennessee Maternal-Fetal Medicine, which is expected to positively impact the company's future revenue streams.
- Financial Impact: The transaction is a cash deal and is anticipated to be immediately accretive to Pediatrix's earnings, further solidifying its leadership position in the maternal-fetal medicine market.
See More
Pediatrix Appoints Two Quality Care Experts
- Executive Appointments: Pediatrix Medical Group has announced the appointment of Dr. James Barry as Chief Clinical Quality & Transformation Officer and Dr. Jochen Profit as Chief Quality Advisor, both renowned for their expertise in care quality, which is expected to enhance the company's service quality for women, babies, and children.
- Quality Improvement Strategy: Dr. Barry will be responsible for shaping the medical direction of the organization, ensuring the highest standards of patient care, and overseeing the work of the Pediatrix Center for Research, Education, Quality and Safety, aimed at improving patient experience and reducing healthcare costs through clinical research and continuous quality improvement.
- Innovation and Leadership: Dr. Barry's contributions in neonatal critical care and medical artificial intelligence will provide strategic advantages for Pediatrix, as his experience will help the company maintain competitiveness in a rapidly evolving healthcare environment.
- Research and Optimization: Dr. Profit's research on optimizing care delivery for pregnant individuals and newborns will provide expert guidance for Pediatrix, advancing the company's efforts in health equity and family-centered care, thereby enhancing patient safety and care quality.
See More
Pediatrix Hosts 47th Annual Neonatology Conference
- Neonatology Conference: Pediatrix Medical Group is hosting the 47th Annual NEO Conference from February 25-27 in Las Vegas, bringing together leading experts to discuss the latest research and innovations in neonatal medicine aimed at improving newborn care outcomes.
- Preterm Birth Rates: The March of Dimes' 2025 Report Card indicates that the national preterm birth rate remains at 10.4%, meaning one in ten newborns is born prematurely, underscoring the ongoing need for innovation in neonatal-perinatal medicine.
- Continuing Education Opportunities: Attendees can earn up to 20 AMA PRA Category 1 Credits and 20 nursing contact hours, reflecting Pediatrix's commitment to enhancing the skills and knowledge of healthcare professionals in the field.
- Hall of Fame Induction: During the conference, Dr. Waldemar Carlo will be inducted into the Legends of Neonatology Hall of Fame, recognizing his pioneering research in neonatal resuscitation and global health initiatives, further advancing neonatal care practices.
See More
Pediatrix Medical Group Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Pediatrix Medical Group reported an adjusted EBITDA of $66 million for Q4 2025, consistent with upwardly adjusted guidance, reflecting robust business volume, acuity, and payer mix, which underscores effective financial control within the organization.
- New Incentive Programs: The introduction of a stock price performance-linked bonus program and the Pediatrix Partners leadership group, comprising 46 physicians receiving stock tracking grants, aims to enhance organizational cohesion and clinical leadership, aligning with the company's strategic objectives.
- 2026 Outlook: Management projects adjusted EBITDA for 2026 to be between $280 million and $300 million, indicating a 5% growth at the midpoint compared to 2025, while anticipating flat revenue, which reflects a cautious approach to market conditions.
- Cash Flow and Share Repurchase: The company generated $115 million in operating cash flow in Q4, down from the previous year, and repurchased 2.9 million shares during the quarter, reducing outstanding shares to approximately 83 million, demonstrating a disciplined approach to capital allocation.
See More
Pediatrix Medical Group Shares Plunge 12% Following Earnings Report
- Disappointing Earnings: Pediatrix Medical Group reported fourth-quarter revenue of nearly $493.8 million, down almost 2% year-over-year, indicating pressure in the competitive healthcare services market, despite analysts' expectations of $486.2 million.
- Declining Net Income: The company's non-GAAP net income fell to $42.5 million ($0.50 per share), down from $43.5 million a year ago, reflecting challenges in cost control amid rising operational expenses.
- Increased Bonus Payouts: The tightening labor market for healthcare professionals led to significantly higher bonus payouts, negatively impacting the company's bottom line and raising investor concerns about future profitability.
- Cautious Future Outlook: Pediatrix anticipates adjusted EBITDA of $280 million to $300 million for full-year 2026, which, while an increase from last year's $275.6 million, still reflects analysts' tepid growth expectations, contributing to diminished market confidence.
See More
Pediatrix Medical Group Reports Q4 2025 Earnings Results
- Financial Performance Overview: Pediatrix Medical Group reported net revenue of $494 million and net income of $34 million for Q4 2025, with an adjusted EPS of $0.50, indicating stable operational capacity despite a slight decline in revenue compared to the previous year, aligning with the company's upwardly revised expectations.
- Same-Unit Revenue Growth: The same-unit revenue increased by 4.0% in Q4 2025, primarily driven by improved collection activities and higher patient acuity, although patient service volumes decreased by 2.7%, demonstrating resilience in market demand, particularly in hospital-based services.
- Cost Control and Adjustments: Operating expenses for Q4 were $444 million, down from $463 million in the prior year, mainly due to the impact of practice dispositions, despite rising clinical compensation costs, reflecting the company's efforts in cost management.
- Future Outlook: Pediatrix anticipates its 2026 adjusted EBITDA to range between $280 million and $300 million, showcasing confidence in future growth, particularly as the company continues to invest in innovation and service quality amid challenges in the healthcare industry.
See More
